kabutan

JCR Pharmaceuticals Co.,Ltd.(4552) Summary

4552
TSE Prime
JCR Pharmaceuticals Co.,Ltd.
561
JPY
+3
(+0.54%)
Apr 28, 3:30 pm JST
3.52
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
559
Apr 28, 8:56 pm JST
Summary Chart Historical News Financial Result
PER
42.7
PBR
1.48
Yield
3.57%
Margin Trading Ratio
17.02
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
558 JPY 3.50 USD
Previous Close Apr 27
558 JPY 3.50 USD
High Apr 28, 3:30 pm
561 JPY 3.52 USD
Low Apr 28, 9:20 am
551 JPY 3.45 USD
Volume
504,500
Trading Value
0.28B JPY 1.76M USD
VWAP
556.76 JPY 3.5 USD
Minimum Trading Value
56,100 JPY 352 USD
Market Cap
0.07T JPY 0.46B USD
Number of Trades
486
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
1,242
1-Year High Jun 2, 2025
15,312
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 252,700 2,704,700 10.70
Apr 17, 2026 227,800 2,677,600 11.75
Apr 10, 2026 214,800 2,809,200 13.08
Apr 3, 2026 224,500 2,621,900 11.68
Mar 27, 2026 245,000 2,586,400 10.56
Company Profile
JCR Pharmaceuticals Co., Ltd. specializes in growth hormone products and focuses on biosimilars. The company collaborates with PeptiDream in creating carrier peptides.
Sector
Pharmaceuticals
JCR Pharmaceuticals Co., Ltd. develops, manufactures, and sells medical pharmaceuticals, regenerative medicine-related products, and pharmaceutical raw materials, primarily targeting rare disease areas. Through its group companies, the company engages in a wide range of activities including purchasing, facility management, market research, clinical trial supervision, pharmaceutical development, and intellectual property management. Internationally, JCR has subsidiaries in Brazil, Europe, and the United States, which handle clinical operations, regulatory affairs, and development tasks. The company also manages the distribution of pharmaceuticals and their raw materials, as well as contract manufacturing. JCR has affiliated companies involved in research and development, manufacturing, and sales in the regenerative medicine field, and has a proven track record in biosimilars.